"10.1371_journal.pone.0098426","plos one","2014-06-10T00:00:00Z","Lea T Drye; David Spragg; D P Devanand; Constantine Frangakis; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Bruce G Pollock; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos; for the CitAD Research Group","Department of Epidemiology and Center for Clinical Trials, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Electrophysiology Laboratory, Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States of America; Division of Geriatric Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States of America; Departments of Epidemiology and Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Clinical Biotechnology Research Institute, Roper St. Francis Healthcare, Department of Health Studies, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States of America; Departments of Psychiatry and Behavioral Sciences and Neurology, Johns Hopkins Bayview and Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, New York, United States of America; Campbell Family Mental Health Research Institute, Division of Geriatric Psychiatry and Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Alzheimers Disease Care, Research and Education Program (AD-CARE), University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Hospital, Baltimore, Maryland, United States of America; Department of Psychiatry and Behavioral Sciences, John Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States of America; Departments of Psychiatry, Neurology, and Gerontology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America; Departments of Medicine (Pulmonary) and Epidemiology and Center for Clinical Trials, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Parkinsons Disease Research, Education and Clinical Center (PADRECC), Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States of America; Aging Clinical Research Center, Mental Illness Research Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Departments of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, United States of America; Memory and Alzheimers Treatment Center, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America","Â¶ Membership of the CitAD Research Group is provided in the Acknowledgments.","The authors have read the journals policy and have the following conflicts. Dr. Porsteinsson reports receiving research funding from Avanir, Baxter, BMS, Elan, EnVivo, Genentech/Roche, Janssen Alzheimer Initiative, Merck, Pfizer, Toyama, Medivation, National Institutes of Health (NIH), and Department of Defense; is a paid consultant for Elan, Janssen Alzheimer Initiative, and Pfizer; is a board member on Data Safety and Monitoring Boards for Quintiles, Functional Neuromodulation, and New York State Psychiatric Institute; participated on a Speakers Bureau for Forest and developed educational presentations for CME, inc. Dr. Pollock reports being a board member on Data Safety and Monitoring Boards for Lundbeck Canada; is a paid consultant for Wyeth; has received travel and accommodation expenses from Lundbeck International Neuroscience Foundation. Dr. Devanand reports receiving grant funding from the NIH and Eli Lilly. Dr. Ismail reports being paid for lectures by Calgary Foothills Primary Care Network, Calgary West Central Primary Care Network, Canadian Conference on Dementia, Alberta College of Family Physicians, and University of British Columbia and is a paid consultant for Astra Zeneca, Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion. Dr. Meinert reports receiving grant funding from the NIH. Dr. Mintzer reports receiving research funding from Accera, Avanir, Baxter, Elan, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen Alzheimer Initiative, Merck, Novartis, Pfizer, Takeda Global Research & Development Center, Wyeth, and NIH; he is employed by Roper St. Francis Healthcare, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, and NeuroQuest and is founder of BioPharma Connex. Dr. Munro reports receiving grant funding from the NIH; being paid for expert testimony from various law firms, Office of Federal Public Defender, and US Attorneys Office; and being paid for lectures for Episcopal Ministries. Dr. Rabins reports being paid for legal testimony from Janssen. Dr. Rosenberg reports receiving research funding from Elan, Eli Lilly, Merck, and Functional Neuromodulation, Inc.; is a paid consultant for Janssen and Pfizer; has developed educational presentations for Eli Lilly. Dr. Schneider reports receiving grant funding from the NIH; is a paid consultant for Forest Laboratories, Eli Lilly, Astra Zeneca, Johnson and Johnson, Bristol Myers Squibb and Otsuka, and Abbott and Abbvie. Dr. Lyketsos reports receiving grant funding from the NIH; is a paid consultant for Avanir, BMS, Elan, Eli Lilly, Genentech, GSK, Janssen, Novartis, NFL, and Pfizer; reports being a board member on Data Safety and Monitoring Boards for Eli Lilly and Janssen; and receiving royalties from Oxford University Press. Drs. Drye, Spragg, Frangakis, Marano, Pelton, Weintraub, Yesavage and Mr. Shade report no conflicts of interest.","2014","06","Lea T Drye","LTD",19,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
